Androgen-Deprivation is Essential in Prostate Cancer Regimen

A joint statement by ASCO and CCO published new guidelines in the treatment of metastatic CRPC.

Indefinite continuation of androgen deprivation therapy (ADT) remains the cornerstone of systemic treatment for metastatic castration-resistant prostate cancer (mCRPC), augmented by new agents, according to a joint guideline from American and Canadian oncology groups.

In addition to ADT (medical or surgical), clinicians should offer patients with mCRPC abiraterone (Zytiga) plus prednisone, enzalutamide (Xtandi), and radium-223 (Xofigo), all of which have favorable benefit-harm profiles, the guideline indicated. Patients also may be offered docetaxel plus prednisone, but should be thoroughly informed of potential toxicity.

Other systemic agents have niche roles in the treatment of mCRPC, as recommended by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO).

Read the complete article: http://bit.ly/1CNc9f2

Source: medpage TODAY

Link to the guidelines: http://bit.ly/1AukPDe